Targeting the serrated pathway of colorectal cancer with mutation in BRAF

Matos, Paulo; Gonçalves, Vânia; Jordan, Peter

doi:10.1016/j.bbcan.2016.06.003

Cited by 8 publications

(4 citation statements)

References 181 publications

(264 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abnormal expression of SRPK1 damages the biological function of SRs, leading to aberrant splicing of pre-mRNA, which can contribute to the progression of cancers [102]. Matos et al reported that SRPK1 could regulate the alternative splicing of Rac1b that enhanced cell cycle progression via NF-kB signaling [103]. SRPK1 contributes to the splicing of Rac1b by inducing the phosphorylation of SRSF1 to further promote its entry into the nucleus [104].…”

Section: Post-translational Modification Of Srs and Cancermentioning

confidence: 99%

Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer

Zheng¹,

Qiu

Wang

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The serine/arginine-rich splicing factors (SRs) belong to the serine arginine-rich protein family, which plays an extremely important role in the splicing process of precursor RNA. The SRs recognize the splicing elements on precursor RNA, then recruit and assemble spliceosome to promote or inhibit the occurrence of splicing events. In tumors, aberrant expression of SRs causes abnormal splicing of RNA, contributing to proliferation, migration and apoptosis resistance of tumor cells. Here, we reviewed the vital role of SRs in various tumors and discussed the promise of analyzing mRNA alternative splicing events in tumor. Further, we highlight the challenges and discussed the perspectives for the identification of new potential targets for cancer therapy via SRs family members.

show abstract

Section: Post-translational Modification Of Srs and Cancermentioning

confidence: 99%

Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer

Zheng¹,

Qiu

Wang

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…SRPK1 activation is associated with splicing of the BRAF and serrated polyp morphology associated, ras-related C3 botulinum toxin substrate 1B (RAC1B) isoform [57,63]. Interestingly formation of a lysine deficient protein kinase 1 (WNK1)/glycogen synthase kinase 3 beta (GSK3B) /SRPK1 complex, was found to be necessary to incur SRSF1 phosphorylation and RAC1B splicing in this study.…”

Section: Colorectal Cancermentioning

confidence: 52%

Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis

et al. 2022

View full text Add to dashboard Cite

Alternative splicing is implicated in each of the hallmarks of cancer, and is mechanised by various splicing factors. Serine-Arginine Protein Kinase 1 (SRPK1) is an enzyme which moderates the activity of splicing factors rich in serine/arginine domains. Here we review SRPK1’s relationship with various cancers by performing a systematic review of all relevant published data. Elevated SRPK1 expression correlates with advanced disease stage and poor survival in many epithelial derived cancers. Numerous pre-clinical studies investigating a host of different tumour types; have found increased SRPK1 expression to be associated with proliferation, invasion, migration and apoptosis in vitro as well as tumour growth, tumourigenicity and metastasis in vivo. Aberrant SRPK1 expression is implicated in various signalling pathways associated with oncogenesis, a number of which, such as the PI3K/AKT, NF-КB and TGF-Beta pathway, are implicated in multiple different cancers. SRPK1-targeting micro RNAs have been identified in a number of studies and shown to have an important role in regulating SRPK1 activity. SRPK1 expression is also closely related to the response of various tumours to platinum-based chemotherapeutic agents. Future clinical applications will likely focus on the role of SRPK1 as a biomarker of treatment resistance and the potential role of its inhibition.

show abstract

“…Adanya mutasi ini berdampak pada mekanisme terapi seperti obat anti-EGFR yang tidak efektif [23]. Berlangsungnya jalur MAPK akibat mutasi BRAF akan membuat sel juga terus berproliferasi [24].…”

Section: Chromosomal Instability (Cin)unclassified

Aspek Genetik Kanker Kolorektal

Rompis

Nyoman

2020

J. Sains Kes.

View full text Add to dashboard Cite

Kanker kolorektal merupakan masalah kesehatan di dunia. Perkembangan kanker kolorektal memerlukan waktu panjang dan berkaitan dengan faktor lingkungan, genetik dan epigenetik. Patogenesis kanker kolorektal melibatkan tiga jalur yang seringkali tumpang tindih yaitu chromosomal instability (CIN), microsatellite instability (MSI) dan CpG island methylator phenotype (CIMP). Dalam tulisan ini dibahas mengenai kanker kolorektal herediter dan sporadik serta aspek genetiknya. Pemahaman mengenai aspek genetik kanker kolorektal sangat berperan dalam manajemen penyakit ini.

show abstract

Targeting the serrated pathway of colorectal cancer with mutation in BRAF

Cited by 8 publications

References 181 publications

Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer

Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer

Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis

Aspek Genetik Kanker Kolorektal

Contact Info

Product

Resources

About